person · Reporting owner

Khattar Jack A.

Disclosed activity across 3 companies

Tapewire entity: 23273
SEC CIK: 0001539937

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COGNITION THERAPEUTICS INCCGTX · Entity 6792	Director	June 17, 2026	June 22, 2026
SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333	Director · President, CEO	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COGNITION THERAPEUTICS INC

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	73,500	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 25,000 · Balance 73,500 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

SUPERNUS PHARMACEUTICALS, INC.

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,258,351	Ending reported balance After 2026-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-12 · Exercise / conversion · Acquired 29,849 · Balance 1,270,993 Row 2 · 2026-08-12 · Tax withholding · Disposed 12,642 · Balance 1,258,351 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-08-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-12 · Exercise / conversion · Disposed 29,849 · Balance 0 F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Common StockSEC Table I · non-derivative	IndirectBy the KBT Trust	958,100	Reported balance Holding disclosure · report date 2026-08-12 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 958,100

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

scPharmaceuticals Inc.

Report date October 07, 2025 · Filed October 07, 2025

Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-07 transaction · row 1 1 source row Row 1 · 2025-10-07 · Other · Disposed 5,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03	Direct	Reported balance After 2025-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11	Direct	Reported balance After 2025-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14	Direct	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18	Direct	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,

F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 12, 2026 Filed Aug 14, 2026 21:12 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	29,849	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-26-000012 · wk-form4_1786741940.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,849 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. F2 · derivative.expiration_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. Read SEC document
August 12, 2026 Filed Aug 14, 2026 21:12 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	12,642	$46.57	$588,737.94	Disclosure SEC source: 0001539937-26-000012 · wk-form4_1786741940.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,258,351 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
August 12, 2026 Filed Aug 14, 2026 21:12 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	29,849	$0.00	$0.00	Disclosure SEC source: 0001539937-26-000012 · wk-form4_1786741940.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,270,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 29, 2026 Filed Jul 31, 2026 21:06 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	29,849	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-26-000010 · wk-form4_1785531995.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,849 Underlying: Common Stock · 29,849 shares Expires not disclosed F1 · derivative.exercise_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. F1 · derivative.expiration_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. Read SEC document
June 17, 2026 Filed Jun 22, 2026 21:18 UTC	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001104659-26-076477 · tm2618497-4_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,500 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document
March 13, 2026 Filed Mar 16, 2026 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	120	$51.75	$6,210.00	Disclosure SEC source: 0001539937-26-000008 · wk-form4_1773691696.xml · nonDerivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the KBT Trust Disclosed balance after: 958,100 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025. Read SEC document
March 13, 2026 Filed Mar 16, 2026 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	10,742	$51.00	$547,842.00	Disclosure SEC source: 0001539937-26-000008 · wk-form4_1773691696.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the KBT Trust Disclosed balance after: 958,220 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $51.54. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 13, 2026 Filed Mar 16, 2026 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	24,138	$50.09	$1,209,072.42	Disclosure SEC source: 0001539937-26-000008 · wk-form4_1773691696.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the KBT Trust Disclosed balance after: 968,962 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.63 to $50.62. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 13, 2026 Filed Mar 16, 2026 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001539937-26-000008 · wk-form4_1773691696.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the KBT Trust Disclosed balance after: 993,100 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly. Read SEC document
March 13, 2026 Filed Mar 16, 2026 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001539937-26-000008 · wk-form4_1773691696.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,241,144 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	38,640	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-26-000006 · wk-form4_1773173627.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	16,574	$54.73	$907,095.02	Disclosure SEC source: 0001539937-26-000006 · wk-form4_1773173627.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,228,644 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
March 06, 2026 Filed Mar 10, 2026 20:13 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	38,640	$0.00	$0.00	Disclosure SEC source: 0001539937-26-000006 · wk-form4_1773173627.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,245,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 28, 2026 Filed Mar 3, 2026 21:12 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	38,640	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-26-000004 · wk-form4_1772572321.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,640 Underlying: Common Stock · 38,640 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document
February 18, 2026 Filed Feb 20, 2026 21:46 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	341,610	$0.00 Strike: $50.20	$0.00	Disclosure SEC source: 0001539937-26-000002 · wk-form4_1771623966.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,610 Underlying: Common Stock · 341,610 shares Expires 2036-02-18 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 18, 2027. Read SEC document
October 09, 2025 Filed Oct 10, 2025 21:33 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	81,250	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,250 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document
October 09, 2025 Filed Oct 10, 2025 21:33 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	1,529	$51.46	$78,682.34	Disclosure SEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,206,578 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.14 to $51.76. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
October 09, 2025 Filed Oct 10, 2025 21:33 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	58,371	$50.55	$2,950,654.05	Disclosure SEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,208,107 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.11 to $51.09. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
October 09, 2025 Filed Oct 10, 2025 21:33 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	81,250	$25.30	$2,055,625.00	Disclosure SEC source: 0001628280-25-044830 · wk-form4_1760132000.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,266,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	6,124	$0.00 Strike: $3.37	$0.00	Disclosure SEC source: 0001193125-25-233528 · ownership.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	16,300	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0001193125-25-233528 · ownership.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	19,750	$0.00 Strike: $4.11	$0.00	Disclosure SEC source: 0001193125-25-233528 · ownership.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.85	$0.00	Disclosure SEC source: 0001193125-25-233528 · ownership.xml · derivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option. Read SEC document
October 07, 2025 Filed Oct 7, 2025 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	OtherCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-25-233528 · ownership.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2 · price: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Units · Derivative	19,320	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F5 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	20,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021. F4 · derivative.expiration_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	7,529	$46.21	$347,915.09	Disclosure SEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,185,228 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	19,320	$0.00	$0.00	Disclosure SEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,192,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	7,796	$46.21	$360,253.16	Disclosure SEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,173,437 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001539937-25-000030 · wk-form4_1759522783.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,181,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 19, 2021. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:18 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,267	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001539937-25-000028 · wk-form4_1759522711.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,250 Underlying: Common Stock · 2,267 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:18 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	1,904	$48.06	$91,506.24	Disclosure SEC source: 0001539937-25-000028 · wk-form4_1759522711.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,161,233 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
October 02, 2025 Filed Oct 3, 2025 20:18 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	2,267	$25.30	$57,355.10	Disclosure SEC source: 0001539937-25-000028 · wk-form4_1759522711.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,163,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
October 01, 2025 Filed Oct 2, 2025 20:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	53,785	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001539937-25-000026 · wk-form4_1759435359.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,517 Underlying: Common Stock · 53,785 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document
October 01, 2025 Filed Oct 2, 2025 20:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	40,173	$48.07	$1,931,116.11	Disclosure SEC source: 0001539937-25-000026 · wk-form4_1759435359.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,160,870 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.25. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
October 01, 2025 Filed Oct 2, 2025 20:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	53,785	$25.30	$1,360,760.50	Disclosure SEC source: 0001539937-25-000026 · wk-form4_1759435359.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,201,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
September 30, 2025 Filed Oct 1, 2025 20:20 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	11,510	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001539937-25-000024 · wk-form4_1759350029.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,302 Underlying: Common Stock · 11,510 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document
September 30, 2025 Filed Oct 1, 2025 20:20 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	8,588	$48.25	$414,371.00	Disclosure SEC source: 0001539937-25-000024 · wk-form4_1759350029.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,147,258 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.44. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
September 30, 2025 Filed Oct 1, 2025 20:20 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	11,510	$25.30	$291,203.00	Disclosure SEC source: 0001539937-25-000024 · wk-form4_1759350029.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,155,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
September 29, 2025 Filed Sep 30, 2025 20:24 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	13,688	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001539937-25-000022 · wk-form4_1759263862.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,812 Underlying: Common Stock · 13,688 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document
September 29, 2025 Filed Sep 30, 2025 20:24 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	10,235	$48.02	$491,484.70	Disclosure SEC source: 0001539937-25-000022 · wk-form4_1759263862.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,144,336 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.14. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
September 29, 2025 Filed Sep 30, 2025 20:24 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	13,688	$25.30	$346,306.40	Disclosure SEC source: 0001539937-25-000022 · wk-form4_1759263862.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,154,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
September 23, 2025 Filed Sep 24, 2025 20:14 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	47,940	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001539937-25-000020 · wk-form4_1758744856.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,940 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
September 23, 2025 Filed Sep 24, 2025 20:14 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	29,513	$47.23	$1,393,898.99	Disclosure SEC source: 0001539937-25-000020 · wk-form4_1758744856.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,140,883 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.55. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
September 23, 2025 Filed Sep 24, 2025 20:14 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	47,940	$12.98	$622,261.20	Disclosure SEC source: 0001539937-25-000020 · wk-form4_1758744856.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,170,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
September 22, 2025 Filed Sep 23, 2025 20:22 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	27,060	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001539937-25-000018 · wk-form4_1758658919.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,940 Underlying: Common Stock · 27,060 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
September 22, 2025 Filed Sep 23, 2025 20:22 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	16,587	$47.02	$779,920.74	Disclosure SEC source: 0001539937-25-000018 · wk-form4_1758658919.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,122,456 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
September 22, 2025 Filed Sep 23, 2025 20:22 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	27,060	$12.98	$351,238.80	Disclosure SEC source: 0001539937-25-000018 · wk-form4_1758658919.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,139,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
September 10, 2025 Filed Sep 12, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Units · Derivative	19,320	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-25-000016 · wk-form4_1757707550.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,320 Underlying: Common Stock · 19,320 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document
September 10, 2025 Filed Sep 12, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	20,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001539937-25-000016 · wk-form4_1757707550.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021. F1 · derivative.expiration_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.